Pharmaceutical Executive
November 12, 2008
News Analysis
0
0
AstraZeneca caused a ruckus at the American Heart Association's annual meeting as data was released proving that its statin not only works for its target indication, but also reduced major CV events in patients who don?t have high cholesterol.
November 12, 2008
News Analysis
0
0
US heparin manufacturer ordered to turn over contaminated batches of heparin. Just how much of the tainted chemical is on the market?
November 12, 2008
News Analysis
0
0
Once considered the future of weight loss drugs, CB-1 antagonists have now been shelved globally. With failures from Pfizer, Merck, and Sanofi-Aventis, analysts say that this is the end of a potential blockbuster therapy.